Zealand Pharma A/S (0NZU.L)

126.80 +8.08 (+6.81%) At close: 05:30PM BST

Zealand Pharma A/S

Sydmarken 11
SOeborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com

Sector(s): 
Industry: 
Full-time employees: 253

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Henriette Wennicke	EVP & CFO	4.85M	N/A	1983
Mr. Ivan Mourits Moller	Executive VP & COO	N/A	N/A	1972
Dr. David M. Kendall M.D.	Chief Medical Officer and Head of R&D	N/A	N/A	1961
Mr. Mads Kronborg	Head of Investor Relations & Communication	N/A	N/A	N/A
Mr. Ravinder Singh Chahil	EVP & General Counsel	N/A	N/A	1968
Ms. Christina Sonnenborg Bredal	Executive VP & Chief People Officer	N/A	N/A	1985
Dr. Jens Damsgaard Mikkelsen M.D.	Head of Molecular Pharmacology	N/A	N/A	N/A
Dr. Danilo Verge	Head of Global Medical Affairs	N/A	N/A	N/A
Lykke Romer	VP & Head of Finance and Accounting	N/A	N/A	N/A
Miriam I. Katz	Assistant Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Corporate governance

Zealand Pharma A/S’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.